Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus
NCT05467514 on ClinicalTrials.gov · last registry update 2023-03-02
A small phase 3 — 35 participants, against a typical 424. The sponsor logged completion for 28 February 2023. Primary outcome, as filed: To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- David Sanchez Garcia
- Sponsor type
- Other Gov
- Enrollment
- 35
- Started
- 2022-07-01
- Primary completion
- 2023-02-28 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus.
Conditions studied
Diabetes Mellitus, Type 1
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.